With $12m in Series C financing, AbSci is looking to tackle the antibody market by accelerating innovation and driving down manufacturing costs using its synthetic biology platform, says CEO.
MediPharma develops ‘smart’ blister to improve patient compliance
from Outsourcing-Pharma.com
AI-informed virtual assistant to help solve ‘stubborn problems,’ says Saama
from Outsourcing-Pharma.com
Serialisation legislation could improve recall process for drugmakers, says exec
from in-PharmaTechnologist.com
Alcami supporting commercial supply of Flexion’s first FDA-approved product
from in-PharmaTechnologist.com
Eisai targets dementia drug discovery with US research facility
Pipelines
ADC Bio: Biotech may 'hold the key' to innovation adoption
Antibody-drug conjugates
GE grows FlexFactory presence in China with another cell therapy plant deal
Cell & Gene Therapies
Gutsy move: Microbiome spin-out seals half-billion-dollar deal with pharma giant
Pipelines
